Protagonist Therapeutics

PTGX · NASDAQ

$137.99+$3.55 (+2.64%)TodayMarket closed · Oct 20, 5:03 PM ET

Prev close $134.44

PTGX analyst rating

BuyConsensus of 15 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy15
Hold0
Underperform0
Sell0

12-month price target · 16 analysts

Average $179.13 (+29.8% upside)

Low: $151.50
Now: $137.99
High: $236.25

Upgrades and downgrades

The latest rating actions, newest first

PTGX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 12, 2026	Initiates	Buy	$184.00	0%
Leerink Partners	Oct 12, 2026	Initiates	Outperform	$150.00 → $190.00	0%
Barclays	Sep 1, 2026	Maintains	Overweight	$153.00 → $180.00	46%
BMO Capital	Sep 1, 2026	Maintains	Outperform	$178.00 → $190.00	46%
Citigroup	Aug 31, 2026	Maintains	Buy	$175.00 → $182.00	60%
HC Wainwright & Co.	Aug 31, 2026	Maintains	Buy	$167.00 → $170.00	50%
BMO Capital	Aug 17, 2026	Maintains	Outperform	$112.00 → $178.00	46%
Truist Securities	Aug 10, 2026	Maintains	Buy	$145.00 → $170.00	51%
Wedbush	Aug 10, 2026	Maintains	Outperform	$118.00 → $173.00	40%
Goldman Sachs	Aug 10, 2026	Upgrade	Neutral → Buy	$110.00 → $186.00	50%

The case for and against

Updated Oct 16, 2026

Bull case

Protagonist Therapeutics is attractive because two FDA approvals have validated its peptide-discovery platform while generating royalty and milestone income that reduces financing risk and supports a self-funded pipeline. Icotrokinra’s strong launch, with over 18,000 prescriptions and about 11,000 patients treated by 7,000 writers, plus the possibility of $8.3B peak PsO sales and $16.8B combined across PsO, PsA, and IBD, suggests a large, underappreciated royalty stream. Rusfertide adds a second royalty source with 14% to 29% worldwide royalties and roughly $700M in peak royalties at $2.9B sales, while $849.5M in cash, $275M in approval-related payments, and a $300M buyback strengthen shareholder returns.

Bear case

Protagonist Therapeutics is viewed negatively because its valuation depends heavily on partnered commercial programs, making execution by Johnson & Johnson and Takeda a key risk while any setback in sales, reimbursement, or uptake could quickly pressure fundamentals. Its wholly owned pipeline adds further uncertainty, since promising early data may not translate into later-stage success, regulatory decisions remain unpredictable, and competition in I&I and oral IL-23R therapies could limit Icotyde and future assets. Financially, higher-than-expected spending on the wholly owned pipeline, combined with standard clinical, manufacturing, funding, and commercial risks, leaves the company vulnerable to uneven development outcomes and weaker returns.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.